Brucellosis in Dogs: Clinical Signs, Serology, and Public Health Risk

Introduction

Canine brucellosis is a globally distributed, zoonotic bacterial infection primarily caused by Brucella canis and, less frequently, by Brucella abortus, Brucella suis, and Brucella melitensis [1, 2]. The disease is characterized by reproductive failure in breeding animals and, in some cases, systemic clinical signs. The intracellular nature of Brucella species complicates both diagnosis and therapy, while the zoonotic potential demands rigorous owner safety measures [3, 4]. This review provides an exhaustive examination of the clinical presentation, serological and molecular diagnostic approaches, and public health implications of canine brucellosis, with a focus on the diagnostic pitfalls inherent in current testing algorithms and the comparative biology of B. canis versus B. abortus infection in dogs.

Causative Agents and Host Range

Members of the genus Brucella are small, Gram-negative, facultative intracellular coccobacilli that lack classical virulence factors such as exotoxins or fimbriae [5]. Their pathogenicity derives from a type IV secretion system (VirB) that enables survival and replication within host macrophages and trophoblasts [6]. Brucella canis is the primary etiological agent of canine brucellosis and is considered host-adapted to dogs [7]. Brucella abortus and B. suis can also infect dogs, particularly those in contact with infected livestock, although such infections often produce milder or subclinical disease [8]. The lipopolysaccharide (LPS) structure of B. canis is rough (R-LPS), lacking the O-polysaccharide side chain found in smooth (S-LPS) species such as B. abortus; this difference has profound implications for serological diagnostic test performance [9].

Pathogenesis and Immune Response

Infection typically occurs via the oral, nasal, or conjunctival routes after contact with aborted fetuses, placental tissues, vaginal discharges, or urine from infected dogs [10]. The bacteria penetrate mucosal surfaces and are phagocytosed by macrophages, where they survive by inhibiting phagolysosome fusion and replicating within the endoplasmic reticulum-derived compartment [11]. A transient bacteremia develops within one to four weeks, lasting for several months to years [12]. The organism localizes to the reproductive tract (prostate, epididymis, uterus), lymphoreticular tissues, and occasionally the intervertebral discs and eyes [13, 14].

The humoral immune response targets both smooth and rough LPS antigens, as well as cytosolic and outer membrane proteins. Immunoglobulin G (IgG) predominates in chronic infection, while IgM appears early during bacteremia [15]. Cell-mediated immunity, particularly Th1-type responses with interferon-gamma production, is critical for control but is typically insufficient to achieve sterile elimination [16].

Clinical Signs

Reproductive Clinical Signs in Breeding Dogs

Reproductive failure is the hallmark of canine brucellosis. In intact males, the most common signs include epididymitis, prostatitis, scrotal dermatitis, testicular atrophy, and infertility [17]. Sperm quality declines due to abnormal morphology and reduced motility. Scrotal enlargement with edema and erythema (scrotal dermatitis) is a pathognomonic finding in some cases [18].

In females, clinical signs include abortion (typically occurring between days 45 and 55 of gestation), embryonic death and resorption, stillbirth, premature delivery, and persistent vaginal discharge that may be serosanguinous or purulent [19]. Failure to conceive and prolonged inter-estrus intervals are common in infected bitches [20].

Non-Reproductive Clinical Signs

Non-reproductive manifestations are less common but include:

• Ocular disease: anterior uveitis, chorioretinitis, endophthalmitis [21].
• Discospondylitis: vertebral endplate infection with associated pain and neurological deficits, most frequently localized to the lumbosacral region [22].
• Polyarthritis: immune-mediated or septic, presenting with lameness and joint effusion [23].
• Meningoencephalitis: rare but reported, with seizures, ataxia, and behavioral changes [24].
• Lymphadenomegaly: generalized or localized to the submandibular and popliteal nodes [25].
• Splenomegaly and hepatomegaly: detectable on abdominal palpation or imaging [26].

Subclinical infection is common, with many seropositive dogs displaying no overt signs. This carrier state poses a significant challenge for disease control in kennel environments [27].

Serological Diagnostics: Principles and Pitfalls

Serology remains the first-line screening modality for canine brucellosis, but test selection must account for the rough phenotype of B. canis.

Rapid Slide Agglutination Test (RSAT)

The RSAT uses 2-mercaptoethanol (2-ME) to reduce IgM and detect IgG agglutinating antibodies against B. canis R-LPS [28]. Sensitivity is high during active infection (greater than 90%), but specificity suffers from cross-reactions with other Gram-negative bacteria, including Bordetella bronchiseptica, Pseudomonas species, and Escherichia coli [29, 30]. False-positive reactions are common in dogs with recent vaccination or respiratory infections. The RSAT is a useful screening tool, but positive results must be confirmed by a secondary method [31].

Agar Gel Immunodiffusion (AGID) Test

The AGID test is considered the serological reference standard for B. canis diagnosis in many laboratories [32]. It detects precipitating antibodies against internal cytosolic antigens of B. canis (cytoplasmic antigen or BASA). The AGID test demonstrates higher specificity than RSAT (greater than 99%), but sensitivity is lower, particularly in early infection when antibody titers are insufficient to form visible precipitin lines [33]. The test requires 48 to 72 hours for completion and is not amenable to point-of-care use.

Enzyme-Linked Immunosorbent Assay (ELISA)

Several commercial and in-house ELISA formats exist, including indirect ELISA (iELISA) and competitive ELISA (cELISA) [34]. For B. canis, iELISA using R-LPS antigen shows sensitivity of 85-95% and specificity of 90-97% [35]. The cELISA is particularly useful for detecting antibodies against smooth Brucella species in dogs, leveraging monoclonal antibodies to the O-polysaccharide epitope [36]. The principal limitation of ELISA is the variable specificity in populations with high background exposure to environmental Gram-negative bacteria. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus illustrates similar principles of antigen capture and signal detection but targets a different pathogen.

Complement Fixation (CF) Test

The CF test is used predominantly for B. abortus surveillance in livestock and occasionally in dogs with suspected smooth Brucella infection [37]. The test is technically demanding, requires careful titration of complement, and is subject to anticomplementary activity in canine serum, limiting its utility.

Diagnostic Pitfalls

These pitfalls necessitate a multi-tier diagnostic algorithm combining serology with molecular methods.

Molecular Diagnostics: PCR and Nucleic Acid Detection

Polymerase chain reaction (PCR) targeting conserved Brucella genes (e.g., bcsp31, IS711, omp25) provides high sensitivity and specificity, with detection limits as low as 10-100 colony-forming units per milliliter of blood or tissue [38, 39]. Real-time quantitative PCR (qPCR) allows quantification of bacterial load and can differentiate B. canis from smooth species using specific primers for the bp26 locus or the vjbR gene [40].

Samples suitable for PCR include:

• Whole blood (EDTA)
• Vaginal or preputial swabs
• Semen
• Aborted fetal tissues (stomach contents, lung, liver)
• Lymph node aspirates
• Urine (centrifuged pellet)

PCR is particularly valuable in cases of suspected false-negative serology, in animals with clinical signs but negative serological results, and for confirmation of positive serological screens [41]. Multiplex PCR panels can simultaneously detect B. canis, B. abortus, B. melitensis, and B. suis [42]. The utility of PCR in resolving diagnostic discordance is analogous to the approach used in Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms, where nucleic acid amplification distinguishes between multiple etiologies.

Sequencing and Genotyping

Molecular typing using multilocus variable-number tandem repeat analysis (MLVA) and whole-genome sequencing provides epidemiological insight into transmission chains [43]. Brucella canis strains show high clonality globally, but MLVA reveals distinct clusters associated with geographic origin [44].

Diagnostic Algorithm

The following Mermaid diagram outlines a recommended diagnostic workflow for canine brucellosis.

flowchart TD
    A[Clinical suspicion: reproductive failure, discospondylitis, or exposure], > B{Initial screening}
    B, > C[RSAT or iELISA for B. canis]
    C, > D{Result}
    D, >|Positive| E[Confirmatory AGID or cELISA]
    D, >|Negative but high suspicion| F[PCR on blood or swab]
    E, > G{AGID positive?}
    G, >|Yes| H[Confirmed infection]
    G, >|No| I[Repeat serology in 2-4 weeks or proceed to PCR]
    F, > J{PCR positive?}
    J, >|Yes| H
    J, >|No| K[Consider alternative diagnoses or repeat PCR on different sample type]
    H, > L[Implement biosecurity: isolation, neuter, inform owner of zoonotic risk]
    L, > M[Serial serology and PCR every 3-6 months to monitor]

This algorithm emphasizes confirmation of positive RSAT results and the use of PCR to resolve ambiguous cases.

Public Health Risk and Owner Safety Measures

Brucella canis is zoonotic, though human infection is less common than with B. abortus or B. melitensis [45]. Human cases typically occur through direct contact with infected dog tissues, blood, urine, or vaginal discharge, especially during obstetrical procedures, sample collection, or laboratory handling [46]. Clinical illness in humans is often mild and nonspecific (fever, headache, myalgia) but can progress to chronic fatigue, arthritis, or neurobrucellosis [47]. Immunocompromised individuals are at greater risk.

Occupational Exposure

Veterinarians, veterinary technicians, kennel staff, and laboratory personnel handling diagnostic specimens from infected dogs face the highest risk [48]. Standard precautions include:

• Wearing gloves, surgical masks, and eye protection when handling tissues, blood, or discharges.
• Performing necropsies and obstetrical procedures in designated areas with biosafety level 2 containment.
• Decontaminating surfaces with 1% sodium hypochlorite or 70% ethanol; Brucella species are susceptible to these disinfectants [49].
• Using biosafety cabinets for culture or sample processing.
• Promptly cleaning any skin abrasions or needle-stick injuries with antiseptic and seeking medical evaluation.

Owner Education

Pet owners should be informed that:

• Canine brucellosis is transmissible to humans, though the risk is low with standard hygiene.
• Pregnant women, young children, and immunocompromised individuals should avoid contact with the dog’s reproductive secretions, urine, or blood.
• Infected dogs should be neutered or spayed to reduce bacterial shedding, and antimicrobial therapy (commonly a combination of minocycline or doxycycline with streptomycin or gentamicin) does not guarantee bacteriological cure [50].
• Euthanasia may be considered for dogs in breeding kennels due to the difficulty of achieving clearance.

The public health context parallels that discussed in Brucellosis in Cattle: Serological Screening, PCR Confirmation, and Eradication Strategies and Brucellosis in Wildlife: Epidemiology, Diagnostic Approaches, and Transmission to Livestock, where multi-species transmission dynamics complicate eradication.

Control and Prevention in Canine Populations

In breeding kennels, the cornerstone of control is test-and-removal combined with strict biosecurity. All newly introduced dogs should undergo a minimum of two serological tests (RSAT and AGID) and a blood PCR at least 30 days apart before entering the facility [27]. Infected dogs should be isolated and either treated under veterinary supervision or removed from the breeding population.

Semen from infected males can transmit the pathogen to females during natural breeding or artificial insemination. Cryopreserved semen should be tested by PCR before use [33]. No commercial vaccine is available for B. canis in most countries, though experimental bacterins have been evaluated [15].

Conclusion

Canine brucellosis remains a diagnostically challenging, zoonotic disease with significant implications for reproductive health in dogs. The rough LPS of B. canis dictates the use of specific serological methods such as RSAT, AGID, and R-LPS ELISA, each with distinct limitations. PCR-based testing provides a confirmatory tool that circumvents the cross-reactivity and sensitivity issues of serology. Public health measures must focus on owner education and occupational safety to minimize human exposure. Integration of serological and molecular diagnostics, as outlined in the proposed algorithm, is essential for accurate diagnosis and effective control in both individual patients and kennel environments.

References

[1] Carmichael, L. E., & Kenney, R. M. (1968). Canine brucellosis: The clinical, pathological, and serological features. Journal of the American Veterinary Medical Association, 152(6), 605-616.

[2] Lucero, N. E., et al. (2005). Brucella canis in humans and dogs. Journal of Clinical Microbiology, 43(3), 1399-1403.

[3] Moriyón, I., et al. (2004). Rough Brucella and the species concept. Veterinary Microbiology, 99(2), 79-88.

[4] Glynn, M. K., & Lynn, T. V. (2008). Brucellosis. Journal of the American Veterinary Medical Association, 233(6), 900-908.

[5] Ficht, T. A. (2003). Intracellular survival of Brucella: Defining the mechanisms. Microbes and Infection, 5(9), 801-810.

[6] Celli, J., et al. (2003). Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. Journal of Experimental Medicine, 198(4), 545-556.

[7] Carmichael, L. E. (1990). Brucellosis in dogs. In: Animal Brucellosis. CRC Press, 269-286.

[8] Forbes, L. B., & Tessaro, S. V. (1996). Infection of dogs with Brucella abortus from cattle. Canadian Veterinary Journal, 37(8), 491-495.

[9] Díaz, R., et al. (1979). The serological diagnosis of brucellosis. Veterinary Record, 105(25), 564-567.

[10] Hollett, R. B. (2006). Canine brucellosis: Outbreaks and management. Veterinary Clinics of North America: Small Animal Practice, 36(3), 601-616.

[11] Gorvel, J. P., & Moreno, E. (2002). Brucella intracellular life: From invasion to intracellular replication. Veterinary Microbiology, 90(1-4), 281-297.

[12] Carmichael, L. E., & Joubert, J. C. (1987). Transmission of Brucella canis by contact exposure. Cornell Veterinarian, 77(1), 62-73.

[13] Kerwin, S. C., et al. (1992). Diskospondylitis associated with Brucella canis infection in dogs. Journal of the American Veterinary Medical Association, 201(10), 1592-1596.

[14] Martin, P. A., & Anderson, J. G. (1989). Ocular manifestations of brucellosis in dogs. Journal of the American Animal Hospital Association, 25(2), 185-191.

[15] Carmichael, L. E., & Shin, S. J. (1996). Canine brucellosis: A diagnostic dilemma. Seminars in Veterinary Medicine and Surgery (Small Animal), 11(3), 161-165.

[16] Golding, B., et al. (2001). Immunity and protection against Brucella. Microbes and Infection, 3(1), 43-48.

[17] Wanke, M. M. (2004). Canine brucellosis. Animal Reproduction Science, 82-83, 195-207.

[18] Greene, C. E., & Carmichael, L. E. (2012). Canine brucellosis. In: Infectious Diseases of the Dog and Cat, 4th ed., Elsevier, 430-441.

[19] Moore, J. A., & Kakoma, I. (1980). Canine brucellosis: A review. Veterinary Medicine/Small Animal Clinician, 75(7), 1091-1097.

[20] Carmichael, L. E. (1966). Abortion in 200 bitches. Journal of the American Veterinary Medical Association, 149(6), 741-746.

[21] Gionfriddo, J. R., & Powell, C. C. (1998). Uveitis associated with systemic disease in dogs. Compendium on Continuing Education for the Practicing Veterinarian, 20(4), 451-462.

[22] Thomas, W. B. (2000). Diskospondylitis in small animals. Veterinary Clinics of North America: Small Animal Practice, 30(1), 161-178.

[23] Bennett, D., & Taylor, D. J. (1988). Canine brucellosis presenting as polyarthritis. Journal of Small Animal Practice, 29(8), 517-526.

[24] Kvitko-White, H. L., et al. (2005). Meningoencephalitis caused by Brucella canis in a dog. Journal of Veterinary Internal Medicine, 19(6), 901-904.

[25] Weber, A., & Schliesser, T. (1985). Incidence of Brucella canis infection in dogs from the Giessen area. Berliner und Münchener Tierärztliche Wochenschrift, 98(3), 85-87.

[26] Hollett, R. B. (2006). Canine brucellosis: Outbreaks and management. Veterinary Clinics of North America: Small Animal Practice, 36(3), 601-616.

[27] Carmichael, L. E. (1991). Brucellosis in dogs. In: Current Veterinary Therapy XI, W.B. Saunders, 278-282.

[28] Zoha, S. J., & Carmichael, L. E. (1982). Serological confirmation of Brucella canis infection. Journal of Clinical Microbiology, 16(1), 113-116.

[29] Carmichael, L. E., & Joubert, J. C. (1988). The rapid slide agglutination test for canine brucellosis: An appraisal. Veterinary Medicine, 83(5), 472-479.

[30] Lucero, N. E., et al. (2002). Evaluation of a rapid slide agglutination test for Brucella canis diagnosis. Veterinary Microbiology, 88(2), 183-191.

[31] Mateu-de-Antonio, E. M., et al. (1994). Comparison of serological tests for the diagnosis of canine brucellosis. Journal of Veterinary Diagnostic Investigation, 6(3), 342-346.

[32] Carmichael, L. E., et al. (1984). The agar gel immunodiffusion test for Brucella canis: Evaluation and standardization. Journal of the American Veterinary Medical Association, 185(11), 1381-1385.

[33] Johnson, C. A., & Walker, R. D. (1992). Clinical significance of serological tests for canine brucellosis. Journal of the American Veterinary Medical Association, 200(9), 1315-1318.

[34] Bercovich, Z., & Ter Laak, E. A. (1990). An ELISA for the detection of antibodies to Brucella canis in dogs. Veterinary Microbiology, 25(1), 85-94.

[35] Lucero, N. E., et al. (1999). Validation of an ELISA for the diagnosis of canine brucellosis. Journal of Veterinary Diagnostic Investigation, 11(5), 427-432.

[36] Nielsen, K., et al. (2004). A competitive ELISA for the detection of antibodies to Brucella abortus and Brucella canis in dogs. Veterinary Microbiology, 101(4), 261-268.

[37] Alton, G. G., et al. (1988). Techniques for the brucellosis laboratory. Institut National de la Recherche Agronomique, Paris.

[38] Bricker, B. J., & Halling, S. M. (1994). Differentiation of Brucella abortus bv. 1, 2, and 4 from Brucella melitensis by PCR. Journal of Clinical Microbiology, 32(11), 2660-2666.

[39] Baily, G. G., et al. (1992). Detection of Brucella melitensis and Brucella abortus by PCR. Journal of Tropical Medicine and Hygiene, 95(4), 271-275.

[40] López-Goñi, I., et al. (2008). Real-time PCR for the diagnosis of brucellosis in dogs. Veterinary Microbiology, 130(1-2), 167-173.

[41] Keid, L. B., et al. (2007). Comparison of PCR and serological tests for detection of Brucella canis in dogs. Veterinary Microbiology, 119(2-4), 252-260.

[42] García-Yoldi, D., et al. (2006). Multiplex PCR for the identification of Brucella species. Journal of Clinical Microbiology, 44(12), 4498-4503.

[43] Whatmore, A. M., et al. (2006). Multilocus variable-number tandem-repeat analysis of Brucella species. Journal of Clinical Microbiology, 44(8), 2896-2906.

[44] Kattar, M. M., et al. (2008). MLVA typing of Brucella canis strains from different geographic origins. Veterinary Microbiology, 131(1-2), 158-166.

[45] Young, E. J. (1995). An overview of human brucellosis. Clinical Infectious Diseases, 21(2), 283-290.

[46] Swartz, M. N., & Thornsberry, C. (2005). Brucella species. In: Principles and Practice of Infectious Diseases, 6th ed., Elsevier, 2222-2230.

[47] Pappas, G., et al. (2005). The new global map of human brucellosis. The Lancet Infectious Diseases, 5(2), 91-99.

[48] Lucero, N. E., et al. (2008). Brucella canis infection in humans: A review. Epidemiology and Infection, 136(4), 453-462.

[49] Cerny, Z., & Rozsypalová, M. (1992). Susceptibility of Brucella canis to disinfectants. Veterinarni Medicina, 37(10), 589-594.

[50] Nicoletti, P. (1991). The treatment of canine brucellosis. In: Current Veterinary Therapy XI, W.B. Saunders, 283-286.